SCHEMBL3344555

SCHEMBL3344555

COC(=O)C(C=O)c1ccc2ncccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.53
HTT P42858 1/20 0.53
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
ALDH1A1 P00352 3/20 0.47
PLK1 P53350 1/20 0.47
NPC1 O15118 3/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
MET P08581 5/20 0.45
RAB9A P51151 2/20 0.44
CYP3A4 P08684 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
NR3C1 P04150 1/20 0.42
PABPC1 P11940 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19926091 0.83 ALOX15 (0.58) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL1669333 0.82 ALOX15 (0.57) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL2697804 0.81 ALOX15 (0.56) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL28562625 0.80 SLC6A3 (0.48) MEN1KMT2A
SCHEMBL19926229 0.80 ALOX15 (0.55) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL17583589 0.77 NPC1 (0.57) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL27809679 0.76 ALDH1A1 (0.50) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL27755472 0.73 AKR1C3 (0.55) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL3656138 0.73 NPC1 (0.49) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL28169181 0.73 AKR1C3 (0.57) ALOX15HTTTAS1R3TAS1R1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS LASSOIE MARIE-AGNES 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS SCN4A, NECTIN4, VPS4B ALOX15 2006/4885HTT 3690/4885TAS1R3 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.